Long-Term Spinal Opioid Therapy in Terminally Ill Cancer Pain Patients

  • Wagemans M
  • Zuurmond W
  • Lange J
12Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In terminally ill cancer patients with refractory pain, long-term spinal opioid therapy may provide a profound analgesia with minimal side effects. The reversibility of the technique and its efficacy throughout the body and for different types of pain are important advantages. For epidural administration, it is preferable to use lipid soluble opioids (sufentanil). For intrathecal administration, morphine is the best choice. The advantages of intrathecal administration over epidural administration are the need for lower doses because of a more direct administration at the receptor site, the easy positioning of the catheter, and less risk for migration of the catheter. In severe refractory pain which does not respond to spinal opioids, the use of non-opioids (e.g., a local anesthetic or an alpha-2 adrenoreceptor agonist) as coanalgesics may be recommended for improving pain relief. Long-term spinal opioid therapy at home has been made possible by technical and organizational development. In home care, only one physician should be the manager for the patient. Coordination should be optimized among patient, family, general practitioner, oncologist, anesthesiologist, home nurse, technician, and pharmacist.

Cite

CITATION STYLE

APA

Wagemans, M. F. M., Zuurmond, W. W. A., & Lange, J. J. (1997). Long-Term Spinal Opioid Therapy in Terminally Ill Cancer Pain Patients. The Oncologist, 2(2), 70–75. https://doi.org/10.1634/theoncologist.2-2-70

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free